List of Mayzent drug patents
Mayzent is owned by Novartis.
Mayzent contains Siponimod Fumaric Acid.
Mayzent has a total of 2 drug patents out of which 0 drug patents have expired.
Mayzent was authorised for market use on 26 March, 2019.
Mayzent is available in tablet;oral dosage forms.
Mayzent can be used as a method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose.
Drug patent challenges can be filed against Mayzent from 2023-03-27.
The generics of Mayzent are possible to be released after 30 November, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 26, 2024 |
| M (M) | Mar 1, 2025 |
Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient
NCE-1 date: 2023-03-27
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
MAYZENT family patents
17
United States
11
Australia
11
European Union
8
China
7
Japan
7
Canada
6
Mexico
5
Brazil
5
Spain
4
Hong Kong
3
Israel
3
Denmark
3
Slovenia
3
Russia
3
Hungary
3
Argentina
3
Portugal
3
Cyprus
3
Poland
3
Taiwan, Province of China
2
South Africa
2
Lithuania
2
Morocco
2
Norway
2
Croatia
2
Peru
2
Korea, Republic of
2
Chile
2
Tunisia
2
New Zealand
1
Austria
1
Jordan
1
Uruguay
1
Singapore
1
Malaysia
1
Netherlands
1
Iceland
1
Ecuador
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic